FIELD: biotechnology.
SUBSTANCE: disclosed are IL-2 muteins binding to subunit IL-2 α receptor, but not having a measurable binding to the subunit IL-2 β receptor. Also disclosed is an isolated nucleic acid encoding an IL-2 mutein, an expression vector and a host cell for producing the IL-2 mutein, pharmaceutical composition for treating IL-2-mediated disease, method of producing mutein IL-2, method of treating IL-2-mediated disease, methods for selective activation of regulatory T cells without activation of CD8+ T cells or selective activation of cells expressing a subunit β IL-2 receptor. Isolated IL-2 mutein contains the amino acid sequence SEQ ID NO: 2, containing one of the following groups of amino acid substitutions: D19N, P33R and E67S; D19N, P33R, V68A and Q73P; D19N, P33R, E67S, V68A and Q73P; D19N, P33R, E67S and N70R; or D19N, P33R, E67S, V68A, N70R and Q73P.
EFFECT: inventions provide selective activation of IL-2R signals in different types of cells for treatment of immune-mediated diseases.
28 cl, 9 dwg, 9 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| PROTEINS SPECIFIC FOR CD137 | 2016 |
|
RU2736312C2 |
| NOVEL PROTEINS SPECIFIC FOR ANGIOGENESIS | 2016 |
|
RU2720688C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) | 2016 |
|
RU2756318C2 |
| AMINOACIL-tRNA SYNTHASE FOR EFFECTIVE INTRODUCTION OF LYSINE DERIVATIVE INTO PROTEIN | 2020 |
|
RU2799794C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
